# An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

> **NCT04145531** · PHASE2,PHASE3 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 229 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Lymphoblastic Leukemia

## Interventions

- **DRUG:** IM JZP-458
- **DRUG:** IV JZP-458

## Key facts

- **NCT ID:** NCT04145531
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-27
- **Primary completion:** 2022-07-13
- **Final completion:** 2022-07-13
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2023-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04145531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04145531, "An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04145531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*